GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart diseases, such as cardiomyopathies, channelopathies, and aortopathies related with sudden cardiac death syndrome. It also provides THROMBO inCode, a genetic test for the diagnosis of hereditary thrombophilia and for assessing the patient's risk of thrombosis; THROMBO inCode reproductive health, a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and risk of ovarian cancer algorithm test product. In addition, the company is involved in Medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.…
GENinCode PLC (9PL.SG) Seasonal returns chart
GENinCode (LON: GENI) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 0.5500 GBp on 20 November 2026, down 73.8% over 52 weeks. Its 52-week range is 0.5000 GBp to 4.900 GBp: the price is 88.8% below the high and 10.0% above the low.
Its market capitalisation is 4.14M GBP.
GENinCode reports an operating margin of -210.1% and revenue down 29.8% year over year.
It holds more cash than debt, a net cash position of 1.89M GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.